Search

Objectives Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV-1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking. The primary 24-week and secondary 48-week analyses of study GS-US-380-4449 (NCT03405935), which assessed the efficacy and safety of switching to B/F/TAF in older PLWH, have been published. Here we report the results of the final 96-week analyses from the study. Methods In this 96-week, phase 3b, open-label, single-arm trial, virologically suppressed PLWH aged >= 65 years switched from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or a tenofovir disoproxil fumarate-based regimen to B/F/TAF. Viral suppression, resistance, immune response, safety, tolerability and adherence were evaluated through week 96. Results Of 90 participants screened, 86 were enrolled and switched to B/F/TAF. No participants had HIV-1 RNA >= 50 copies/ml (by FDA Snapshot algorithm) at weeks 72 or 96; virologic suppression rates were 94.2% (81/86; 95% CI 87.0-98.1) and 74.4% (64/86; 95% CI 63.9-83.2), respectively. No treatment-emergent resistance was observed, and CD4 counts remained stable. There were no study drug-related serious adverse events. Three participants experienced drug-related treatment-emergent adverse events that led to premature drug discontinuation. There were no clinically relevant changes from baseline to week 96 in fasting lipid parameters, and the median change in body weight at week 96 was 0.0 kg (IQR -2.3, 2.0). Median self-reported adherence was 100% (IQR 100-100%). Conclusions Switching to B/F/TAF is an effective long-term option for virologically suppressed adults >= 65 years of age, with favourable safety and tolerability profiles in this population.

Amines bearing a sulfonamide and a carbamate protecting group undergo a base mediated rearrangement to form the unexpected products (II) and (IV).

To investigate similarities between patients who experience chronic tinnitus or pain and to formulate treatment strategies that are likely to be effective for patients who experience phantom auditory pain.A total of 160 patients rated the severity and loudness of their tinnitus and completed the State-Trait Anxiety Inventory (STAI) and an abbreviated version of the Beck Depression Inventory (aBDI). Patients received counseling, audiometric testing, and matched the loudness of their tinnitus to sounds played through headphones.A specialized tinnitus clinic within an urban medical center.Tinnitus severity was highly correlated with patients' degree of sleep disturbance, STAI, and aBDI scores. The self-rated (on a 1-to-10 scale)--but not the matched--loudness of tinnitus was correlated with tinnitus severity, sleep disturbance, STAI, and aBDI scores.The severity of chronic tinnitus is correlated with the severity of insomnia, anxiety, and depression. These relationships are the same for many patients with chronic pain. Treatment recommendations are discussed in reference to these results.

Objectives:1) Describe the differences in distortion product otoacoustic emissions (DPOAE) and automated auditory brainstem response (AABR) results in premature infants in the neonatal intensive care unit (NICU) with noise exposure. 2) Discuss optimal newborn hearing screen protocols for capturing at-risk NICU graduates.Methods:Prospective observational outcomes study from August to the present. Subjects: Admissions to the NICU

The combination of pot, atom and step economy (PASE) in the synthesis of organic molecules of medium complexity can lead to a significant 'greening' of a synthetic route. This is demonstrated by the synthesis of highly substituted tetrahydropyran-4-ones and is quantified by a series of recognised metrics, which demonstrate the efficiency of combining PASE over conventional synthetic strategies.